News We’re Watching: Philips And Walgreens Settlements, ReCor Readies For Takeoff, Farapulse Trial Results
Executive Summary
This week, Philips announced a legal settlement on recalled CPAPs and BiPAPs; the FDA released emergency preparation recommendations; ReCor prepared to bring Paradise RDN to the US market; and Abbott released the results of a trial comparing optical coherence tomography (OCT) to angiography for guidance during cardiac surgery.
You may also be interested in...
Cardio Catch-Up: Advisory Panel Gives Recor Momentum Toward US Launch Of RDN System
The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.
Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry
Medtech Insight’s Cardiovascular Catch-Up highlights recent news on cardiovascular tech innovations that you may have missed. This edition recaps the presentation of results from EU PORIA, a European registry atrial fibrillation patients treated with Boston Scientific's Farapulse pulsed field ablation system.
AdvaMed Offers Plan To Strengthen Medtech Supply Chain
Medtech trade group AdvaMed is offering a list of recommendations to beef up the nation’s medical technology supply chain. Public-private partnerships are central to the group’s plan.